|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Results were expressed in five different ways and showed significantly fewer %CD4+CD25+ T lymphocytes expressing FoxP3 in blood of older dogs (>/=7 years) compared with the other two age groups (<2 and 2-6 years) (p<0.001) and fewer %CD4+CD25+FoxP3+ Tregs in the tumor draining lymph nodes of OSA patients compared to the unrelated lymph node (p=0.049).
|
20197202 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Induction of CD4(+) CD25(+) FoxP3(+) T regulatory (Treg) cells has been implicated in the tumour immune escape mechanism, although the novel anti-cancer treatment strategies targeting Treg cells remain unknown.
|
25284464 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, in the clinical setting, CD4(+) CD25(hi) T regulatory cells (Treg) present within the tumor microenvironment may be potent suppressors of tumor-targeted effector T cells.
|
21487038 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas.
|
17216339 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD4+CD25+regulatory T cells (T(reg)) impair anti-tumor and anti-viral immunity.
|
21997230 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have investigated the diagnostic value of an antibody against CD25 for the immunohistochemical detection of MCs in bone marrow sections in 73 patients with SM and 75 control cases (reactive marrow, n = 54; myelogenous neoplasms, n = 21) and correlated the results with the presence of c-kit mutations.
|
15371947 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We evaluated the effects of celecoxib treatment on tumor-infiltrating lymphocyte (TIL) subsets [CD3(+), CD4(+),CD8(+), CD25(+), and T cell receptor (TCR)-zeta-expressing cells] and tryptase-positive mast cells in cervical tumors.
|
16609015 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Because of the low number of CD25-positive tumor cells in high-grade tumors, the usefulness of CD25 as a tumor marker is, however, questionable.
|
22446323 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD4+CD25+FOXP3+ regulatory T cells (Treg) inhibit the anti-tumour immune response and reduce the effect of cancer immunotherapy.
|
28253320 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have previously shown that human squamous cell carcinomas (SCC) express the interleukin 2 receptor (IL2R)-alpha and -beta chains, and that the ligand, IL2, directly inhibits growth of the tumor in vitro and in vivo in the tumor xenograft-nude mice model.
|
7523315 |
1994 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Further analysis showed that the percentage of CD4(+)CD25(+)CD127(low) Tregs and the expression of FoxP3 mRNA were closely associated with tumor node metastasis (TNM) staging in elderly patients with NSCLC.
|
22884069 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We demonstrate that during immunity to a tumor/self-Ag, the predominant role of Th cell-derived IL-2 was to maintain IL-2Ralpha (CD25) on CD4(+) T regulatory cells (T(reg)), which resulted in their maintenance of the T(reg) cell lineage factor, Forkhead/winged helix transcription factor (Foxp3), and tolerance.
|
16621991 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The substance secreted in tumor microenvironment recruited CD4(+)CD25(+) Treg cells to tumor sites to contribute to the prosperity and growth of the tumors.
|
20221638 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The combination of three agents significantly enhanced the antitumor efficacy as assessed by tumor size, tumor markers in the serum (human soluble interleukin-2 receptor-α and β2-microglobulin) and survival of the MT-1 tumor-bearing mice, compared with all other treatment groups (P<0.05).
|
25118879 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment with the combination of TNFR2-blocking antibody and a CD25-targeted antibody also resulted in enhanced inhibition of tumor growth in a syngeneic 4T1 mouse model of breast cancer.
|
29295954 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
An increased population of CD4(+)CD25(high)Foxp3(+) regulatory T cells (Tregs) in the tumor-associated microenvironment plays an important role in cancer immune evasion.
|
25223704 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data suggest that in NSCLC patients, there is an increase of CD4(+)CD25(high)FOXP3(+) regulatory T-cells in the peripheral blood and tumor microenvironment.
|
19538059 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data showed that >80% of CD4(+)CD25(+) T cells isolated from PBMC and tumor sites express FoxP3.
|
20012605 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In light of this, we evaluated the impact of induced regulatory T (iTreg) cells on the efficacy of tumour cell killing redirected by ImmTAC and demonstrated down-regulation of T-cell proliferation and expression of CD25, CD107a, Granzyme B and Perforin by ImmTAC-redirected T cells.
|
29791021 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The enhanced anti-tumor immunity in response to the CD25 depletion or CTLA-4 blockade was only seen in the immunogenic TRAMP-PSA tumor model, whereas the effect was completely absent in mice bearing poorly immunogenic TRAMP-C1 tumors.
|
25111463 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Electrochemical immunoassay for the tumor marker CD25 by coupling magnetic sphere-based enrichment and DNA based signal amplification.
|
31098719 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
FOXP3 and CD25 double staining antibody cocktails identify regulatory T cells in different types of tumor tissues using tissue microarrays.
|
30502715 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD4(+)CD25(+)Foxp3(+) T-regulatory cells (Tregs) accumulate in tumors; however, little is known about how the tumor environment influences this process.
|
21098714 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The relative clinical safety and efficacy of administering anti-CD25 radioimmunoconjugates and immunotoxins in various haematological tumour indications has been established and clinical trials of a novel CD25-directed antibody drug conjugate are underway.
|
28556984 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Its molecular design aims to (i) avoid preferential activation of regulatory T-cells vs. immune effector cells by removing CD25 binding; (ii) increase the therapeutic index of IL-2 therapy by (a) preferential retention at the tumor by having a lower dissociation rate from CEA-expressing cancer cells vs. IL-2R-expressing cells, (b) avoiding any FcγR-binding and Fc effector functions and (c) reduced binding to endothelial cells expressing CD25; and (iii) improve the pharmacokinetics, and thus convenience of administration, of IL-2.
|
28405498 |
2017 |